Screener
Bio-Techne TECH Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056302
| Line item | Nine Months Ended / March 31, 2026 | Nine Months Ended / March 31, 2025 |
|---|---|---|
| Borrowings under line-of-credit agreement | — | 38,000 |
| Repayments of long-term debt | (146,000) | (27,000) |
| Taxes paid on RSUs and net share settlements | (10,643) | (6,288) |
| Net cash provided by (used in) financing activities | (135,906) | (163,453) |
| Effect of exchange rate changes on cash and cash equivalents | (1,985) | (1,434) |
| Net change in cash and cash equivalents | 47,633 | (11,121) |
| Cash and cash equivalents at beginning of period | 162,186 | 151,791 |
| Cash and cash equivalents at end of period | $209,819 | $140,670 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Bio-Techne's financing cash flow?
- Bio-Techne (TECH) reported financing cash flow of -$42.72M in Q1 2026.
- How has Bio-Techne's financing cash flow changed year-over-year?
- Bio-Techne's financing cash flow increased by 37.2% year-over-year, from -$68.05M to -$42.72M.
- What is the long-term trend for Bio-Techne's financing cash flow?
- Over 2 years (2022 to 2025), Bio-Techne's financing cash flow has grown at a 2.3% compound annual growth rate (CAGR), from -$242.85M to -$253.91M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Bio-Techne's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude